四年前，56 岁的 Sherry Hambly 出现了疼痛的皮疹，经常感觉自己好像被严重晒伤了。她每次洗手或洗澡时，皮肤都会灼伤，肌肉乏力。经过漫长的寻找答案之旅，她被诊断为患有皮肌炎，这是一种自身免疫性疾病。她现在正在密歇根州特洛伊市的 Option Care Health 输液室接受静脉注射免疫球蛋白 (IVIG)，她很庆幸自己能重获新生。

在找到正确的诊断和治疗方法之前，Sherry 由于身体虚弱，每天都要吃止痛药，几乎不能从事会计工作。她睡不好觉，筋疲力尽，无法享受带给她快乐的事情，包括与孙子孙女玩耍、打高尔夫球、打保龄球和做瑜伽。

“我很喜欢特洛伊市输液室的员工，因为我从来不必费力气——他们会打理好一切事项，确保我的护理计划专为我量身定制。”密歇根州罗切斯特希尔斯市的 Sherry 说道。

早期，她在服用羟氯喹，一种高剂量的类固醇和抗排斥药。她最初的 IVIG 处方是每月一次，连续 3 天每天 4 小时的 IVIG 输液，但到了月底，效益逐渐消失，她没有精力去办公室。Option Care Health 团队与 Sherry、她的医生和药剂师一起制定了最适合她的护理计划，现在她每隔一周接受两天的输液。

“这让我的世界发生了翻天覆地的变化。”她说。“我不再服用任何止痛药，完全摆脱了我赖以维持活动的所有类固醇，因为我的 IVIG 治疗非常有效。”

她与丈夫、儿子和孙子孙女一起生活。现在，她已经恢复了精力，可以帮助自己 11 岁的孙子在家上学，并照看 16 个月大的孙女。她又开始打高尔夫，做瑜伽，可以充分发挥自己的工作潜力。

“我真的很喜欢输液室——在疫情期间呆在自己的小空间里真好——房间有窗户、舒适的椅子和厨房，我可以在那里加热咖啡。“这里很安静，我甚至可以在那里工作。”她说。“工作人员总是不遗余力地确保我们的安全和舒适。”

35 岁的 Cambria Hooven 经常患肺炎、支气管炎和其他严重感染，她很少与人接触，也很少出门。在最终了解到她近乎持续生病的原因是由于普通变异性免疫缺陷病 (CVID) 导致免疫系统衰弱后，她开始通过 Option Care Health 在家中接受静脉注射免疫球蛋白 (IVIG)。她有更多的自由去参加社交活动，但后来新冠疫情爆发。

由于 Cambria 害怕冒险让访客到她家，因此她的 Option Care Health 护士 Kola 制定了一个计划。他建议她到他工作的 Option Care Health 兰霍恩市输液室接受治疗，那里离她在费城的家有 35 分钟的车程。

“我很紧张，因为我在这次疫情期间哪里都不敢去，所以他在我第一次预约前给我发了一个输液室的视频，向我展示了一切，并确切告诉我该进什么门。”Cambria 说道，回想起来时热泪盈眶。“Kola 两年来一直是我的护士，他对我来说就像家人一样。我不知道我的生活中要是没有他该怎么办！”

现在，她在一个干净且经过消毒的房间里接受每月四小时的治疗，房间内配备有舒适的躺椅和大窗户。由于在疫情期间其他时候她都会待在家里，因此她非常享受每月一次的输液治疗。“这是一个小小的休养中心。”Cambria 说道。

Cambria 最终得到诊断并接受了治疗，让她如释重负。多年来，她接连求医，试图弄清楚为什么她总是生病。八年前，她切除了阑尾，得了严重的血液感染，在医院住了 33 天，不知道自己能否活下来。为了弄清自己的问题，她毅然辞去了儿童福利社工的工作，接受了一项又一项的检测。

最后她找到了一名免疫专家，诊断出她的病情并开出了 IVIG 处方。结果，此后她没有住过院。起初，她在家中开始自我输液，但并不适应。Option Care Health 推荐了一名护士到她家提供输液服务，就这样她认识了 Kola。

现在她正在接受治疗，Cambria 感觉更健康了，而且可以远程从事社工工作，经常在兰霍恩市输液室工作。

“我知道如何保持安全，我在 Option Care Health 获得的治疗帮助了我，所以我不必生活在恐惧和孤独中。我可以安全地外出远足和背包旅行。”她说。“去兰霍恩市输液室真是太好了，那里安全干净，我非常尊重护士和他们的家属。他们体贴入微。”

BANNOCKBURN, Ill., November 29, 2016 — Option Care Enterprises, Inc., one of the nation’s leading providers of home and alternate treatment site infusion services, has been selected as a contracted provider of a new 20% formulation of subcutaneous immunoglobulin (SCIG) therapy for primary immunodeficiency (PI). CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] is manufactured by Shire plc.

CUVITRU™ recently was approved by the U.S. Food and Drug Administration to treat adult and pediatric patients two years and older with PI, a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly.

“Option Care has a proven track record of providing compassionate, high-quality clinical care in the home or at alternate treatment sites to patients undergoing therapy for a variety of complex conditions, including those with primary immunodeficiency,” said Lisa Betts, Vice President, Specialty Programs, Option Care. “As one of the largest national providers of immunoglobulin therapy, we are pleased to offer CUVITRU™ to support primary immunodeficiency patients as we continue to spread awareness and improve treatment options. “

Immunoglobulin (IG) is a lifelong therapy provided to prevent recurrent infections in patients with PI, which affects as many as six million people worldwide.

Option Care 拥有由超过 1,800 多名临床专家组成的工作团队，包括药剂师和 1,200 多名输液护士。这支由经过专门培训的临床医师组成的多学科团队提供个性化的患者护理计划、临床监测每次输液，以及全面的患者和照料者教育。要获取更多信息，请致电 Option Care 的 IG 专科卓越中心：1-877-974-4844 或传真：877-974-4845。

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all acute and chronic patients across the United States. Learn more at www.OptionCare.com.

###

2016 年 3 月 1 日起，Option Care Enterprises, Inc. 将成为家庭静脉注射和皮下注射免疫球蛋白 (IVIG/SCIG) 药物的首选提供者，[*]成员可继续接受当前隶属于参与 Independence Blue Cross 提供者网络的医院或健康系统之家庭输液供应商的 IVIG/SCIG。适用于 Independence Blue Cross 隶属机构的承保成员。[*]Independence Blue Cross 是一家控股公司，不是“承保保险”的实体名称或实体名义。

作为全美最大的家庭和备选医疗站点输液服务提供者，Option Care 经过专门培训的护士和药剂师向接受复杂病况治疗的患者（包括接受免疫球蛋白治疗的患者）提供高品质、高接触的临床支持。Option Care 免疫球蛋白 (IG) 患者对于 Option Care 为帮助患者管理其病况而安排的家庭访视和持续的电话支持报以极高的满意度 — 98%。[*]Option Care Enterprises, Inc. 2016 年存档数据。

IG 治疗是面向免疫系统相关病症患者的处方疗法，这些病症包括原发性免疫缺陷疾病（身体免疫系统不能正常运作）、自身免疫性疾病（身体攻击本身）和其他受益于治疗的病症。提供 IG 治疗的方法有两种：IVIG 是通过静脉进行注射，SCIG 则是通过皮下的脂肪组织进行注射。包括 IVIG 和 SCIG 在内，Option Care 每年管理着超过 55,000 例 IG 输液。[*]Orange J, Kirkham H, Ayer G, et al.通过专业药房或家庭输液服务来改善接受免疫球蛋白治疗的患者的临床疗效。论文发表于美国过敏、哮喘和免疫学会 (ACAAI) 2015 年科学年会：2015 年 11 月 5-9 日；圣安东尼奥。

在最近一项创新研究中，与大型国家数据库中记录的在其他环境中接受 IG 治疗的患者相比，接受了高水平临床监督的 Option Care 家庭 IG 患者拥有更好的疗效。

Option Care 可提供所有 IG 产品，公司 1,700 多位临床医师（包括经过 IVIG/SCIG 专门培训的护士和药剂师）提供高品质的护理，包括个性化的患者护理计划、临床监测每次输液，以及全面的患者和照料者教育。

Effective March 1, 2016, Option Care Enterprises, Inc. will be a preferred provider of intravenous and subcutaneous immunoglobulin (IVIG/SCIG) drugs provided in the home* for members covered by AmeriHealth New Jersey.

As one of the nation’s largest providers of home and alternate treatment site infusion services, Option Care’s specially trained nurses and pharmacists provide high-quality, high-touch clinical support to patients treated for complex conditions, including those receiving IG.  Option Care IG patients report very high levels of satisfaction — 98 percent — with Option Care’s in-home visits and ongoing support calls to help them manage their conditions.[*]Option Care Enterprises, Inc. Data on file 2016.

IG therapy is prescribed to patients with immune system-related conditions, including primary immunodeficiency disorders (the body’s immune system doesn’t function properly), autoimmune disorders (the body attacks itself) and other conditions that benefit from the treatment. IG therapy is delivered one of two ways: IVIG is infused through a vein, and SCIG is delivered into the fatty tissue just below the skin. Including IVIG and SCIG, Option Care manages more than 55,000 IG infusions each year.[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.

Home Infusion IG Therapy in Focus

在最近一项创新研究中，与大型国家数据库中记录的在其他环境中接受 IG 治疗的患者相比，接受了高水平临床监督的 Option Care 家庭 IG 患者拥有更好的疗效。

Option Care 可提供所有 IG 产品，公司 1,700 多位临床医师（包括经过 IVIG/SCIG 专门培训的护士和药剂师）提供高品质的护理，包括个性化的患者护理计划、临床监测每次输液，以及全面的患者和照料者教育。

*Members 可继续接受当前隶属于参与 AmeriHealth 新泽西提供者网络的医院或健康系统之家庭输液供应商的 IVIG/SCIG。

SAN ANTONIO — Option Care patients treated with immunoglobulin (IG) therapy at home with a high level of clinical oversight had better outcomes compared to others receiving the therapy according to a first-of-its-kind study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting this week. The researchers, who evaluated data from Option Care as compared to a large national database, also determined that the cost of therapy was lower. [*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.

One of the nation’s largest providers of home and alternate treatment site infusion services, Option Care provides high-quality, high-touch clinical support to patients undergoing treatment for complex conditions, including those receiving IG. Option Care’s unique treatment model combines locally delivered care with nationally managed treatment protocols and outcomes data collection. Specially trained infusion nurses and pharmacists provide individualized, expert IG treatment and patient education in the home. Patient-reported outcome measures — a scientific way of capturing patient experience — are collected by a dedicated team of IG experts and shared with patient’s broader health care team to keep everyone on the same page about the patient’s health status and to optimize the treatment plan.

“We conducted this research to test the hypothesis that patients who receive higher levels of clinical care in the home end up having better outcomes, ” said Jordan Orange, M.D., Ph.D., lead investigator of the study and professor of pediatrics and immunology at Baylor College of Medicine in Houston. “We found that the provision of comprehensive and consistent care in a patient’s own home does indeed lead to better outcomes. And an added benefit was that it was actually more cost effective.”

IG 疗法的提供对象是免疫系统疾病患者，如免疫缺陷或自身免疫性疾病（包括某些神经肌肉疾病）患者。治疗的护理地点可以是医院住院部、医院门诊输液中心、医生办公室、社区输液中心或家中。

在一项从 2011 年 8 月 1 日至 2014 年 6 月 30 日的回顾性研究中，Orange 博士和他的同事评估了接受家庭 IG 疗法的 Option Care 患者与一个大型国家行政索赔数据库 (IMS Pharmetrics Plus) 中所包含对照组患者的疗效对比。患者以两种方式之一接受治疗：直接注射到血液中的静脉 IG (IVIG) 和注射到第一层皮肤下方的皮下 IG (SCIG)。研究人员将每名 Option Care 患者与数据库中的四名患者进行配对：227 名 Option Care IVIG 患者与 908 名对照组患者相比较，59 名 Option Care SCIG 患者与 236 名对照组患者相比较。研究人员发现：

• Serious bacterial infections were lower in Option Care IVIG patients (.16 per patient per year) compared to control IVIG patients (.29 per patient per year)[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.  
• Serious adverse events (renal impairment, hepatitis, anaphylaxis and aseptic meningitis) were lower in Option Care SCIG patients (.08 per patient per year) compared to SCIG control patients (.34 per patient per year). [*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
• Costs were lower overall for Option Care IVIG patients compared to controls ($112,756 vs. $120,567 per patient per year).[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.  

“Delivering high quality care for all of our patients is our top priority. We believe that our high-touch care model benefits patients, and we are pleased that this IG data bears that out,” said Paul Mastrapa, CEO of Option Care. “Not only do our patients appreciate the quality of life benefits of receiving care in the home, this research shows they also are getting the best quality care at a lower cost.”

关于美国过敏、哮喘和免疫学会 (ACAAI)

The ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit  www.AllergyandAsthmaRelief.org.

关于 Option Care

Option Care Enterprises, Inc.（前身为 Walgreens Infusion Services）由经过专门培训的输液护士、药剂师和营养师提供高品质的临床护理，医治各式急性、慢性和罕见疾病的患者。作为全美最大的家庭和备选医疗站点输液服务提供者之一，Option Care 在美国各地拥有 92 家输液药房和 110 个备选医疗站点。有关详情请访问 www.OptionCare.com。 

# # #

媒体联系人信息

Option Care
Lauren Kotarski
312-558-1770
LKotarski@pcipr.com